id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S10173 R37194 |
Blotière (Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 | Hypospadias | 1st trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
2.49 [0.64;9.67] C excluded (control group) |
3/517 7/2,997 | 10 | 517 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10048 R36445 |
Blotière (Topiramate) (Controls unexposed NOS) (Mixed indications), 2019 | Hypospadias | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 3.40 [0.70;10.20] | 3/517 3,371/1,875,733 | 3,374 | 517 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8575 R28527 |
Tomson (Topiramate), 2018 | Hypospadias | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 2.77 [0.33;23.14] C | 1/152 6/2,514 | 7 | 152 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10221 R37443 |
Hernández-Díaz (Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2012 | Hypospadias | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 21.90 [1.05;457.19] C | 2/359 0/1,562 | 2 | 359 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8569 R28511 |
Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 | Hypospadias/genitourinary tract defects | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 3.96 [0.46;34.03] C | 1/28 6/647 | 7 | 28 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 4 studies | 4.03 [1.56;10.45] | 3,390 | 1,056 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Topiramate) (Controls unexposed NOS) (Mixed indications; 2: Topiramate; 3: Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications; 4: Topiramate) (Controls exposed to Lamotrigine, sick;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 10173